• EAACME Accredited CME

    Take part in our EACCME accredited educational activity entitled ‘The future of urticaria – advances in CSU research’ based on materials from EAACI 2017.

  • Case studies

    Doctor Montse Alvaro presents a case study of an 8-year-old girl who presents with a 3-month history of near-daily urticaria and asymmetrical facial swelling.
    Additional case studies from Marcus Maurer, Peter Schmid-Grendelmeier, Torsten Zuberbier and more.

  • 5th Pediatric Allergy and Asthma Meeting (PAAM 2017)

    Co-chair Doctor Montse Alvaro reviews the meeting that gives a clear message to GPs and paediatricians regarding diagnostic tests, patient referral and treatment with antihistamines.

  • PCP Checklist

    How does urticaria differ from diffuse acute eczema, anaphylaxis or insect bites?
    Click here to view our downloadable PCP checklist which has been designed to aid the diagnosis and managment of CSU in primary care.

  • TARGET My Hives

    Target My Hives is the app that is bringing patients with CSU together and helps patients stay in control by monitoring their symptoms.
    Follow others sith similar symptoms, join the community, follow patient associations, help researchers in their understanding.

  • Paediatric Urticaria

    The impact on younger patients and how diagnosis and management compares to the recommendations for adult patients with CSU.

 

Chronic Spontaneous Urticaria (CSU) Knowledge Centre

Welcome to the CSU Knowledge Centre. Featuring an overview of chronic spontaneous urticaria, offering pages that cover epidemiology, burden of disease, pathophysiology, assessment tools, treatment, paediatricsguidelines and fast facts. Delve into the Disease Overview to further your understanding of chronic spontaneous urticaria.

Information focusing on primary care, containing videos of patients’ first-hand experiences, video highlights and presentations from key events and real-life case studies presented by experts in the field is also available. Resources include: frequently asked questions in urticaria answered by key opinion leaders, quick reference guides including diagnostic algorithms, and information about the TARGET My Hives application.

Recently added: Our new EACCME accredited CME, based on presentations given at the epgonline .org-sponsored symposium ‘The future of urticaria – advances in CSU research’ at the EAACI annual meeting in June 2017.

 

Paediatric Urticaria

Paediatric Urticaria

Paediatric urticaria - its impact and how diagnosis and management compares to adult recommendations. Doctor Montse Alvaro discusses the challenge of managing paediatric patients where it's strongly recommended that first-generation H1-antihistamines are not prescribed.

Focus on Primary Care

Focus on Primary Care

Quick reference guides and case study videos dedicated to helping primary care practitioners diagnose, manage and treat. Professor Ana Gimenez-Arnau and Dr Dermot Ryan helped with the development of a downloadable checklist with algorithms, disease and drug information.

e-Learning

e-Learning

Access the accredited CME 'EAACI 2017: The future of urticaria – advances in CSU research' and the e-Learning activity 'Case consults: Changing paradigms in the age of biologics', downloading a certificate upon completion.

Symposia Media Library

Symposia Media Library

Watch highlights from key speakers including Marcus Maurer and Marter Ferrer at past events within the fields of dermatology and clinical immunology, such as PAAM, GUF, EADV, EAACI, RADLA and WCD.

Resources

Resources

FAQs such as how should the UAS7 be used, quick reference guides including a decision tree for wheals/angioedema and diagnostic tests recommended in the EAACI/GA2LEN/EDF/WAO guidelines are some of the resources available.

FAQs

FAQs

Frequently asked questions are answered by our expert faculty including Christian Vestergaard, Marta Ferrer and Ana Giménez-Arnau and include 'How do you chose which antihistamine to use in a newly diagnosed patient?'.

Fast Facts

Fast Facts

12 key points on understanding chronic spontaneous urticaria including: there are currently no validated useful biomarkers and there is currently no known cure with first-line treatment of H1-antihistamines, showing less than 50% symptomatic relief.

Treatment

Treatment

Discover first-, second- and third-line treatment options for CSU following the EAACI/GA2LEN/EDF/WAO recommended treatment algorithm. Detailing second generation H1-antihistamines and add-ons including omalizumab, ciclosporin A and montelukast.

Login/ Register Maximise Minimise